Wells Fargo analyst Brandon Couillard initiates coverage on GeneDx Hldgs (NASDAQ:WGS) with a Equal-Weight rating and announc...

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

TD Cowen analyst Dan Brennan maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $46 to $50.

BTIG analyst Mark Massaro maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $35 to $45.

Craig-Hallum analyst Bill Bonello maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $43 to $46.

Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and raises the price target from $28 ...

GeneDx Hldgs (NASDAQ:WGS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.30) b...

Faster Turnaround Time for Rapid Whole Genome Sequencing (rWGS), Buccal Sample Types and Additional Repeat Expansions to Become...